|
1) Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of athero-sclerosis. N Engl J Med. 2011; 364: 1746-60
|
|
|
|
2) Smith SA, Mutch NJ, Baskar D, et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A. 2006; 103: 903-8
|
|
|
|
|
|
3) Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A. 2007; 104: 6388-93
|
|
|
|
|
|
4) Maas C, Govers-Riemslag JW, Bouma B, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest. 2008; 118: 3208-18
|
|
|
|
|
|
5) van der Meijden PE, Munnix IC, Auger JM, et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood. 2009; 114: 881-90
|
|
|
|
|
|
6) Muller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009; 139: 1143-56
|
|
|
|
|
|
7) White-Adams TC, Berny MA, Tucker EI, et al. Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Arterioscler Thromb Vasc Biol. 2009; 29: 1602-7
|
|
|
|
|
|
8) Emsley J, McEwan PA, Gailani D. Structure and function of factor XI. Blood. 2010; 115: 2569-77
|
|
|
|
|
|
9) Papagrigoriou E, McEwan PA, Walsh PN, et al. Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol. 2006; 13: 557-8
|
|
|
|
|
|
10) Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem. 1991; 266: 7353-8
|
|
|
|
|
|
11) Gailani D, Broze GJ, Jr. Factor XI activation in a revised model of blood coagulation. Science. 1991; 253: 909-12
|
|
|
|
|
|
12) Kravtsov DV, Matafonov A, Tucker EI, et al. Factor XI contributes to thrombin generation in the absence of factor XII. Blood. 2009; 114: 452-8
|
|
|
|
|
|
13) Pedicord DL, Seiffert D, Blat Y. Feedback activation of factor XI by thrombin does not occur in plasma. Proc Natl Acad Sci U S A. 2007; 104: 12855-60
|
|
|
|
|
|
14) Maas C, Meijers JC, Marquart JA, et al. Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. Proc Natl Acad Sci U S A. 2010; 107: 9083-7
|
|
|
|
|
|
15) Ruiz FA, Lea CR, Oldfield E, et al. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem. 2004; 279: 44250-7
|
|
|
|
|
|
16) Hernandez-Ruiz L, Saez-Benito A, Pujol-Moix N, et al. Platelet inorganic polyphosphate decreases in patients with delta storage pool disease. J Thromb Haemost. 2009; 7: 361-3
|
|
|
|
|
|
17) Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009; 15: 1318-21
|
|
|
|
|
|
18) Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010; 107: 15880-5
|
|
|
|
|
|
19) Caen J, Wu Q. Hageman factor, platelets and polyphosphates: early history and recent connection. J Thromb Haemost. 2010; 8: 1670-4
|
|
|
|
|
|
20) Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood. 2008; 112: 2810-6
|
|
|
|
|
|
21) Smith SA, Choi SH, Davis-Harrison R, et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood. 2010; 116: 4353-9
|
|
|
|
|
|
22) Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol. 2007; 27: 2507-13
|
|
|
|
|
|
23) Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood. 2008; 112: 3555-62
|
|
|
|
|
|
24) Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005; 202: 271-81
|
|
|
|
|
|
25) Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006; 203: 513-8
|
|
|
|
|
|
26) Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood. 2008; 111: 4113-7
|
|
|
|
|
|
27) Decrem Y, Rath G, Blasioli V, et al. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med. 2009; 206: 2381-95
|
|
|
|
|
|
28) Hagedorn I, Schmidbauer S, Pleines I, et al. Factor XIIa inhibitor recombinant human albumin infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation. 2010; 121: 1510-7
|
|
|
|
|
|
29) Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 2010; 116: 4684-92
|
|
|
|
|
|
30) Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood. 2009; 113: 936-44
|
|
|
|
|
|
31) Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010; 116: 3981-9
|
|
|
|
|
|
32) Guerrini M, Beccati D, Shriver Z, et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol. 2008; 26: 669-75
|
|
|
|
|
|
33) Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008; 358: 2457-67
|
|
|
|
|
|
34) Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contami-nated heparin. N Engl J Med. 2008; 359: 2674-84
|
|
|
|
|